[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100247310":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":25,"studyPopulation":11,"armGroups":26,"interventions":37,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":43,"collaborators":11,"id":45,"slug":11,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":11,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":11,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":11,"overallStatus":63,"whyStopped":11,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":11},{"fullName":5,"class":6},"The First People's Hospital of Changzhou","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"Progression-Free-Survival (PFS)",null,"1 month",[14],{"measure":15,"description":11,"timeFrame":12},"Overall Survival (OS)",[17],{"measure":18,"description":11,"timeFrame":12},"Lactic Dehydrogenase (LDH)",{"allocation":20,"interventionModel":21,"interventionModelDescription":11,"primaryPurpose":22,"observationalModel":11,"timePerspective":11,"maskingInfo":23},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":24,"maskingDescription":11,"whoMasked":11},"NONE","Autologous cytokine-induced killer (CIK) cells transfusion(\\>2\\*10\\^9 cells count) within 2 weeks after regular chemotherapy every 3 months.",[27,31],{"label":28,"type":29,"description":30,"interventionNames":11},"regular chemotherapy","NO_INTERVENTION","Patients after chemotherapy are just followed up.",{"label":32,"type":33,"description":34,"interventionNames":35},"CIK regimen","EXPERIMENTAL","Patients after chemotherapy will receive at least 3 cycles of Cytokine-induced killer cells (CIK) treatment every 3 months.",[36],"Biological: Cytokine-induced killer cells (CIK)",[38],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":11},"BIOLOGICAL","Cytokine-induced killer cells (CIK)","Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.",[32],{"type":44,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100247310",false,"NCT02497898","Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma","A Randomized Controlled Clinical Trial of Cytokine-induced Killer (CIK) Cells Treatment in Patients With Refractory Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* diagnosed as non-Hodgkin lymphoma with negative effect of regular chemotherapy, and need further therapy\n\nExclusion Criteria:\n\n* patients refuse the therapy or have no tolerance for the therapy","ALL","18 Years","80 Years",{"count":55,"type":56},1000,"ESTIMATED","INTERVENTIONAL",[59],"PHASE2","The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and\u002For chemoresistant lymphomas.",[62],"Lymphoma, Non-Hodgkin","NOT_YET_RECRUITING","2015-07-12",{"date":66,"type":56},"2015-07-15",{"date":68,"type":11},"2015-07",{"date":70,"type":56},"2040-07",{"name":5,"class":6}]